

The Galapagos patient partnership charter



Galapagos

Pioneering for patients



Galapagos discovers, develops and brings to patients novel medicines in the field of inflammation, fibrosis and kidney diseases. Our roots are grounded in research. By studying disease processes, we work to unlock new treatments to help patients better manage their conditions, day to day. With this Patient Partnership Charter, we deepen our commitment to patients.

The Charter sets out our ambition, underpinned by our company's values and principles, to pioneer for patients by working in close partnership with patients and patient organizations.

Our ambition

Our ambition is to be a trusted partner to the patient community. We commit to collaborate with patients across the lifecycle of medicines. Starting with early research and discovery, we foster partnerships in the design and implementation of clinical trials, all the way through to providing patients with new treatment options and beyond.

By working with patients, for patients, we believe we can pursue better patient outcomes. Together, we can make a meaningful difference for individuals living with medical conditions, their caregivers and their families.

We will work to achieve this by establishing mutually beneficial, long-lasting and trust-based relationships with the patient community. Through collaboration and co-creation, we will enhance understanding of our respective objectives and priorities, and adopt an inclusive and balanced mindset, which will help to bring new and needed therapies to patients.

Our commitments

We have co-developed a set of core commitments, together with patients, patient representatives and advocates. These commitments will be at the heart

of our partnerships with patients, in line with applicable laws and regulations on patient-pharma interactions.

Together with our partners, we



Establish a shared purpose

Starting from the needs of every partner, we focus on defining common long-term goals

We believe that co-creation is valuable and mutually beneficial, and we endeavor to seek early input in our projects

We jointly assess the impact of our partnership and work together to ensure our collaborations are bringing the expected results



To build a partnership of equals

We value and respect our partners' independence, their experience, expertise and knowledge

We look to challenge & encourage each other to meet our common goals

We support our teams to engage with relevant patients and patient organizations in sustainable partnerships, to better understand the patient perspective and incorporate it in our ways of working



In a transparent way

We foster open communication and the exchange of quality information

Together, we ensure there is a clear understanding and definition of mutually agreed roles and responsibilities

We disclose all relevant information about our activities with partners, and pre-empt any potential conflicts of interest



For more information about Galapagos, please visit www.glpag.com.

Acknowledgement

We would like to thank Luisa Avedano, CEO of the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), Nicola Bedlington, independent patient advisor, Neil Betteridge, independent patient advisor, Nicholas Brooke, Founder and Executive Director of Patient Focused Medicine Development (PFMD), Sue Farrington, President of the Federation of European Scleroderma Associations (FESCA), Ilaria Galetti, Vice-President of FESCA, Liam Galvin, CEO of the European Pulmonary Fibrosis Federation (EU-IPFF), Steve Jones, President of EU-IPFF, Alastair Kent, independent patient advisor, and Mitchell Silva, Chair of EUPATI Belgium vzw, for their collaboration, contributions and guidance in developing this Patient Partnership Charter.

Galapagos
Pioneering for patients